Results from the pivotal GLAGOV (GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound) randomized clinical trial, investigating evolocumab (Repatha) in statin-treated patients, were published on January 1, 2017. The study assessed the effect of evolocumab on the progression of coronary disease, as detailed in the publication.
Background
The GLAGOV trial focused on evolocumab, a drug studied for its potential impact on coronary artery disease progression. It specifically investigated its effects in patients already receiving statin therapy.
Trial design
The GLAGOV trial was a randomized clinical trial designed to evaluate the effect of evolocumab on the progression of coronary disease. The study population consisted of patients who were already undergoing statin treatment. The primary assessment involved measuring changes in coronary plaque using intravascular ultrasound.
What this means
The publication of the GLAGOV trial results makes the detailed findings on evolocumab's effect on coronary disease progression available to the scientific and medical community. Clinicians and researchers can now review the complete data regarding the drug's impact in statin-treated patients, particularly concerning plaque regression as measured by intravascular ultrasound.
Source
The information regarding the GLAGOV trial results was published on January 1, 2017. The details are available via PubMed, hosted at pubmed.ncbi.nlm.nih.gov, under the headline 'Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.'